- English (USA)
- English (UK)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Innocare Pharma Ltd (9969)
The Innocare share price today is 13.63, view HK 9969 stock exchange data. Track the latest Innocare share price with real-time updates on 9969 stock performance including market cap, day range, 52-week range and dividend yield. Access 9969 charts, earnings dates and analyst estimates to support your investment decisions.
13.63
-1.16(-7.84%)
Closed·
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
13.17
14.17
52 wk Range
9.65
20.18
9969 is not included in our AI-picked strategies. See which stocks are.
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
13.1714.17
52 wk Range
9.6520.18
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Book Value / Share
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Book Value / Share
9969 Scorecard
Company’s Health
Assesses a company's financial position by analysing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Strong Sell
Analysts Sentiment
Strong Buy
Price Target
19.01
Upside
+39.49%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Impressive gross profit margins
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Sell
Analyst Ratings
9 Buy
0 Hold
0 Sell
Ratings:
9 analysts
Overall Consensus
Strong Buy
Analysts 12-Month Price Target:
Average 19.01
(+39.49% Upside)
Earnings
Latest Release
24-08-2026
EPS / Forecast
0.08 / --
Revenue / Forecast
608.43M / --
Compare 9969 to Peers and Sector
Metrics to compare | 9969 | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship Relationship9969PeersSector | |
|---|---|---|---|---|
P/E Ratio | 28.3x | −2.5x | −0.4x | |
PEG Ratio | 0.06 | 0.05 | 0.00 | |
Price/Book | 3.4x | 5.1x | 2.6x | |
Price / LTM Sales | 9.3x | 12.8x | 3.0x | |
Upside (Analyst Target) | 28.5% | 47.8% | 56.4% | |
Fair Value Upside | Unlock | 0.8% | 7.9% | Unlock |
InnoCare Pharma Limited, a biopharmaceutical company, engages in discovering, developing, and commercializing drugs for the treatment of cancer and autoimmune diseases in China. The company develops Orelabrutinib, an BTK inhibitor to treat patients with relapsed and/or refractory (r/r) chronic lymphocytic leukemia, r/r mantle cell lymphoma, r/r Waldenstrom’s macroglobulinemia, r/r marginal zone lymphoma, r/r diffuse large B-cell lymphoma (DLBCL)- MCD, r/r central nervous system lymphoma, combo w/MIL-62, systemic lupus erythematosus, immune thrombocytopenia purpura, multiple sclerosis, and neuromyelitis optica spectrum disorder. It also developing ICP-B02 to treat CD20+B-cell malignancies; ICP-B05 to treat hemato-oncology; ICP-248 to treat chronic lymphocytic leukemia; ICP-332 to treat atopic dermatitis; ICP-488 to treat psoriasis; ICP-538 to treat autoimmune diseases; zurletrectinib (ICP-723) to treat neurotrophic tyrosine receptor kinase fusion positive cancers; ICP-189 to treat non-small cell lung cancer; and ICP-B05 to treat solid tumor. The company has research collaboration and license agreement with Eli Lilly and Company to develop new medicines. InnoCare Pharma Limited was incorporated in 2015 and is headquartered in Beijing, China.
Ownership
Ownership Overview
Top Holders
FAQ
What Is the Innocare (9969) Share Price Today?
The Innocare share price today is 13.63.
What is the current Innocare (9969) share price and day range?
As of 02-10-2026, the Innocare share price is 13.63, with a previous close of 14.79. The share price has ranged from 13.17 to 14.17 today, while the 52-week range spans from 9.65 to 20.18.
What Is the Innocare Market Cap?
As of today, Innocare market cap is 28.76B.
What Is the Innocare (9969) Share Price Target?
The average 12-month share price target for Innocare is 19.01, with a high estimate of 22.78876536 and a low estimate of 8.89057929. 9 analysts recommend buying, while 0 suggest selling, with an overall rating of Strong Buy and +39.49% Upside potential.
What Is Innocare's Earnings Per Share (TTM)?
The Innocare EPS (TTM) is 0.51.
From a Technical Analysis Perspective, Is 9969 a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.
What Stock Exchange Does Innocare Trade On?
Innocare is listed and trades on the Hong Kong Stock Exchange.
What Is the Stock Symbol for Innocare?
The stock symbol for Innocare is "9969."
How Many Times Has Innocare Stock Split?
Innocare has split 0 times.
How Many Employees Does Innocare Have?
Innocare has 1388 employees.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.